Loxo Oncology to Present at the JMP Securities Life Sciences Conference

STAMFORD, Conn., June 14, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that Joshua H. Bilenker, M.D., chief executive officer, will present a corporate overview at the JMP Securities Life Sciences Conference in New York City on Wednesday, June 22, 2016 at 2:30PM ET.

A live webcast of the presentation will be available at http://ir.loxooncology.com/.

About Loxo Oncology

Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible.

Contacts for Loxo Oncology, Inc.Company:Jacob S. Van NaardenChief Business Officer[email protected] 

Investors:Peter Rahmer The Trout Group, LLC 646-378-2973[email protected]

Media:Dan Budwick Pure Communications, Inc. 973-271-6085[email protected] 

You May Also Be Interested In

• Analysts Reveal 10 Top 100x Coins to Watch in 2026 as Apeing’s Upcoming Presale Enters Final 5-Day Countdown 
• Mid Island Y JCC Announces Historic Naming Gift from Dr. Harvey Manes and the Manes Peace Prize Foundation; Agency to Become Manes JCC
• AM Best Affirms Credit Ratings of Sammons Financial Group, Inc. and Its Subsidiaries